Law & Regulation
Adastra reports record sales in 2023, but remains in the red
The jump in sales was primarily attributed to higher demand for Adastra’s in-house brand, but growth was offset by a increase in spending on marketing.
The…
Canadian cannabis processor and producer Adastra Holdings Ltd. (CSE: XTRX) reported its financial results for the fourth quarter and fiscal year ending Dec. 31, 2023, showing its highest sales haul yet, which was coupled with a rise in net loss.
For the fiscal year, the company posted gross revenue of C$37.7 million, marking a 108% increase over the previous year. After excise taxes, net revenue came out to C$22.2 million, up 67% from C$13.3 million in the same period the year before.
The jump in sales was primarily attributed to higher demand for Adastra’s in-house brand, which was met with increased production at the company’s facility in Langley, British Columbia.
Still, Adastra posted a net loss of C$3.54 million in 2023, a 17% rise from the previous year. The company cited increased spending on marketing initiatives to boost brand awareness as the main reason for the higher loss.
According to filings, auditors noted material uncertainty “that may cast significant doubt” on the company’s ability to continue as a going concern. As of Dec. 31, 2023, Adastra had a working capital deficiency of around C$6 million and a deficit of C$21.7 million.
However, Adastra generated record cash from operating activities of C$1.9 million for the year.
Looking ahead, Adastra said it expects to maintain its growth momentum and has already achieved new milestones, including a record single purchase order of C$1 million in March.
“Moreover, we’re committed to a renewed focus on cost-saving measures aimed at ensuring profitability,” interim CEO Lachlan McLeod said.
The firm during the year also received permission from the Canadian government to sell limited amounts of cocaine and psilocybin to pharmacies, hospitals, and researchers. The license allows the company to sell up to 1,000 grams of psilocybin and “interact” with 250 grams of cocaine, as well as import coca leaves for manufacturing and synthesizing cocaine.
While it didn’t exactly mean the legalization of such substances for recreational use in Canada, McLeod said at the time it was announced that the company would “evaluate how the commercialization of this substance fits in with our business model.”
The post Adastra reports record sales in 2023, but remains in the red appeared first on Green Market Report.
legalization psilocybin-
Psilocybin1 week ago
Psychedelic Underground Celebrated in San Francisco on Bicycle Day Weekend
-
Psychedelics5 days ago
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Psychedelics6 days ago
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Law & Regulation4 days ago
Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Psychedelics6 days ago
Cybin to Participate at the 27th Annual Milken Institute Global Conference
-
Psychedelics5 days ago
Behold! A New Mushroom Emoji Has Arrived!
-
Ketamine5 days ago
DEA poised to move cannabis to Schedule III
-
Psychedelics5 days ago
Behold! A New Mushroom Emoji Has Arrived!